ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announced that it has retained Lucosky Brookman LLP, a distinguished corporate finance and securities law firm, to assist in evaluating an uplisting to a senior national securities exchange such as the Nasdaq...
2025-03-03 9:00 AM EST
ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that its first therapeutic mRNA candidate from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics") has demonstrated encouraging anti-cancer activity in a mouse...
2025-01-14 9:27 AM EST
ME Therapeutics Holdings Inc. Appoints Chief Business Officer
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce the appointment of Karim Lalji as Chief Business Officer. "We are excited to be able to announce the addition of Karim Lalji as Chief Business Officer," said Salim Dhanji, PhD, Chief Executive Officer of...
2024-10-25 9:00 AM EDT
ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to update investors on the progress of our research and development and corporate development plans. G-CSF Antibody Candidate Update The Company is continuing to advance our lead anti-G-CSF antibody candidate,...
2024-10-22 6:00 AM EDT
ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). As previously disclosed, ME...
2024-09-18 9:00 AM EDT
ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce a strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). This partnership aims to test the delivery and efficacy of mRNA-based drug candidates targeted to myeloid cells. ME...
2024-07-08 11:31 AM EDT
ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company has engaged two new clinical consultants to help advance our lead anti-G-CSF antibody candidate (h1B11-12) towards a first in-human clinical trial. Dr. Kate Hanham, PhD, is a clinical trial...
2024-05-29 9:00 AM EDT
ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company will be presenting at the Investor Clubhouse during the RBC Canadian Open PGA golf tournament presented by Investor.Events. ME Therapeutics will be presenting on Friday, May 31st, 2024,...
2024-05-17 9:00 AM EDT
ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's management will be ringing the opening bell for the Canadian Securities Exchange on Wednesday April 17, 2024, and invites its shareholders to tune in at 930am EST to participate in the celebration. "We are honoured to be...
2024-04-15 11:10 AM EDT
ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's CEO, Dr. Salim Dhanji, will attend and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled to take place at the Metro Toronto Convention Centre in Toronto from April...
2024-03-26 8:00 AM EDT
ME Therapeutics Announces Closing of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, announces the closing of its previously announced non-brokered private placement financing (the "Offering") and has issued 1,555,000 units (each, a "Unit") at a price of $1.00 per Unit raising gross proceeds of $1,555,000. Each...
2024-03-06 8:00 AM EST
ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce a non-brokered private placement financing to raise gross proceeds of up to $1,550,000 (the "Offering") and to provide an update on the status of its current research and development programs. The...
2024-02-27 3:45 PM EST
ME Therapeutics Holdings Inc. Announces Listing on the Frankfurt Stock Exchange (FSE) and the Completion of Its Redesigned Website
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - ME Therapeutics Holdings Inc. (CSE: METX), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce that the Company's common shares are now listed on the Frankfurt Stock Exchange (FSE) under the symbol Q9T. "Listing on the Frankfurt Stock Exchange is an important step for the Company as it provides us with an opportunity to expand our investor...
2023-12-11 8:30 AM EST